We evaluated the outcome of 482 children with acute myeloid leukemia (AML) enrolled in the Associazione Italiana di Ematologia e Oncologia Pediatrica AML 2002/01 trial. Treatment was stratified according to risk group; hematopoietic stem cell transplantation (HSCT) was used in high-risk (HR) children. Patients with core binding factor leukemia achieving complete remission (CR) after the first induction course were considered standard risk (SR; 99 patients), whereas the others (n = 383) were assigned to the HR group. Allogeneic (ALLO) or autologous (AUTO) HSCT was employed, respectively, in 141 and 102 HR patients after consolidation therapy. CR, early death, and induction failure rates were 87%, 3%, and 10%, respectively. Relapse occurred in 24% of patients achieving CR. The 8-year overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 68%, 55%, and 63%, respectively. OS, EFS, and DFS for SR and HR patients were 83%, 63%, and 66% and 64%, 53%, and 62%. DFS was 63% and 73% for HR patients given AUTO-HSCT and ALLO-HSCT, respectively. In multivariate analysis, risk group, white blood cell > 100 x 10(9)/L at diagnosis, and monosomal karyotype predicted poorer EFS. Risk-oriented treatment and broad use of HSCT result in a long-term EFS comparing favorably with previously published studies on childhood AML.

Pession, A., Masetti, R., Rizzari, C., Putti, M. C., Casale, F., Fagioli, F., Luciani, M., Lo Nigro, L., Menna, G., Micalizzi, C., Santoro, N., Testi, A. M., Zecca, M., Biondi, A., Pigazzi, M., Rutella, S., Rondelli, R., Basso, G., Locatelli, F., Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia, <<BLOOD>>, 2013; 122 (2): 170-178. [doi:10.1182/blood-2013-03-491621] [https://hdl.handle.net/10807/244095]

Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia

Locatelli, Franco
2013

Abstract

We evaluated the outcome of 482 children with acute myeloid leukemia (AML) enrolled in the Associazione Italiana di Ematologia e Oncologia Pediatrica AML 2002/01 trial. Treatment was stratified according to risk group; hematopoietic stem cell transplantation (HSCT) was used in high-risk (HR) children. Patients with core binding factor leukemia achieving complete remission (CR) after the first induction course were considered standard risk (SR; 99 patients), whereas the others (n = 383) were assigned to the HR group. Allogeneic (ALLO) or autologous (AUTO) HSCT was employed, respectively, in 141 and 102 HR patients after consolidation therapy. CR, early death, and induction failure rates were 87%, 3%, and 10%, respectively. Relapse occurred in 24% of patients achieving CR. The 8-year overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 68%, 55%, and 63%, respectively. OS, EFS, and DFS for SR and HR patients were 83%, 63%, and 66% and 64%, 53%, and 62%. DFS was 63% and 73% for HR patients given AUTO-HSCT and ALLO-HSCT, respectively. In multivariate analysis, risk group, white blood cell > 100 x 10(9)/L at diagnosis, and monosomal karyotype predicted poorer EFS. Risk-oriented treatment and broad use of HSCT result in a long-term EFS comparing favorably with previously published studies on childhood AML.
2013
Inglese
Pession, A., Masetti, R., Rizzari, C., Putti, M. C., Casale, F., Fagioli, F., Luciani, M., Lo Nigro, L., Menna, G., Micalizzi, C., Santoro, N., Testi, A. M., Zecca, M., Biondi, A., Pigazzi, M., Rutella, S., Rondelli, R., Basso, G., Locatelli, F., Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia, <<BLOOD>>, 2013; 122 (2): 170-178. [doi:10.1182/blood-2013-03-491621] [https://hdl.handle.net/10807/244095]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/244095
Citazioni
  • ???jsp.display-item.citation.pmc??? 65
  • Scopus 149
  • ???jsp.display-item.citation.isi??? 139
social impact